MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ijms241411829

Медицинская библиотека · International journal of molecular sciences · 2023

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.

Ntanasis-Stathopoulos Ioannis, Malandrakis Panagiotis, Fotiou Despina, Migkou Magdalini, Theodorakakou Foteini, Roussou Maria, Eleutherakis-Papaiakovou Evangelos, Spiliopoulou Vassiliki, Kastritis Efstathios, Terpos Evangelos, Dimopoulos Meletios-Athanasios, Gavriatopoulou Maria

СтатьяПеревод пока не подготовлен

Аннотация

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41-81) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4-10). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0-7), whereas the median PFS among the responders was 12 months (95%CI: 6-18). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2-3 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit.

Для цитирования: Ntanasis-Stathopoulos Ioannis, Malandrakis Panagiotis, Fotiou Despina, Migkou Magdalini, Theodorakakou Foteini, Roussou Maria, Eleutherakis-Papaiakovou Evangelos, Spiliopoulou Vassiliki, Kastritis Efstathios, Terpos Evangelos, Dimopoulos Meletios-Athanasios, Gavriatopoulou Maria. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.. International journal of molecular sciences. 2023. DOI: 10.3390/ijms241411829.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.